Inflammation as a cause of venous thromboembolism

Critical Reviews in Oncology/Hematology

Volumn 99, Issue , 2016, Pages 272-285

  Saghazadeh, Amene ^a,b   Rezaei, Nima ^a,c,d  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b NeuroImmunology Research Association (NIRA)   (Iran)

^c UNIVERSAL SCIENTIFIC EDUCATION AND RESEARCH NETWORK USERN   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Deep vein thrombosis; Genetics; Inflammation; Pulmonary embolism; Venous thromboembolism

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 6; AUTACOID;

AGING; AUTOIMMUNE DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; GENE TARGETING; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEART DISEASE; HIGH RISK PATIENT; HORMONE SUBSTITUTION; HUMAN; INFECTION; INFLAMMATION; INJURY; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; OBESITY; PREGNANT WOMAN; REVIEW; SURGICAL APPROACH; VENOUS THROMBOEMBOLISM; ANIMAL; COMPLICATION; FEMALE; METABOLISM; PREGNANCY;

ANIMALS; FEMALE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; PREGNANCY; VENOUS THROMBOEMBOLISM;

EID: 84959463642     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2016.01.007     Document Type: Review

References (136)

1. A pilot randomized double-blind comparison of a low-molecular-weight heparin A nonsteroidal anti-inflammatory agent, and placebo in the treatment of superficial vein thrombosis. Arch. Internal Med. 2003, 163:1657-1663.
2. Aadland E., Odegaard O.R., Roseth A., Try K. Free protein S deficiency in patients with chronic inflammatory bowel disease. Scand. J. Gastroenterol. 1992, 27:957-960.
3. Acosta J.A., Yang J.C., Winchell R.J., Simons R.K., Fortlage D.A., Hollingsworth-Fridlund P., et al. Lethal injuries and time to death in a level I trauma center. J. Am. Coll. Surg. 1998, 186:528-533.
4. Ahlehoff O., Gislason G.H., Lindhardsen J., Charlot M.G., Jørgensen C.H., Olesen J.B., et al. Psoriasis carries an increased risk of venous thromboembolism: a Danish nationwide cohort study. PloS One 2011, 6:e18125.
5. Alikhan R., Cohen A.T., Combe S., Samama M.M., Desjardins L., Eldor A., et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch. Internal Med. 2004, 164:963-968.
6. Ananthakrishnan A.N., Cagan A., Gainer V.S., Cheng S.C., Cai T., Scoville E., et al. Thromboprophylaxis is associated with reduced post-hospitalization venous thromboembolic events in patients with inflammatory bowel diseases. Clin. Gastroenterol. Hepatol. 2016, 2014.
7. Ates A., Aydintug O.T., Duzgun N., Yaman O., Sancak T., Omur N.D. Behcet's disease presenting as deep venous thrombosis and priapism. Clin. Exp. Rheumatol. 2004, 22:107-109.
8. Aue G., Nelson Lozier J., Tian X., Cullinane A.M., Soto S., Samsel L., et al. Inflammation TNFalpha and endothelial dysfunction link lenalidomide to venous thrombosis in chronic lymphocytic leukemia. Am. J. Hematol. 2011, 86:835-840.
9. Bagratuni T., Kastritis E., Politou M., Roussou M., Kostouros E., Gavriatopoulou M., et al. Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens. Am. J. Hematol. 2013, 88:765-770.
10. Baron J.A., Gridley G., Weiderpass E., Nyren O., Linet M. Venous thromboembolism and cancer. Lancet 1998, 351:1077-1080.
11. Baser O., Liu X., Phatak H., Wang L., Mardekian J., Kawabata H., et al. Venous thromboembolism prophylaxis and clinical consequences in medically ill patients. Am. J. Ther. 2013, 20:132-142.
12. Bashashati M.R., Habibi H., Keshavarzian A., Schmulson M.A., Sharkey K. Intestinal microbiota: a regulator of intestinal inflammation and cardiac ischemia?. Curr. Drug Targets 2015, 16:199-208.
13. Bean C.J., Boulet S.L., Ellingsen D., Trau H., Ghaji N., Hooper W.C., et al. Increased risk of venous thromboembolism is associated with genetic variation in heme oxygenase-1 in Blacks. Thromb. Res. 2012, 130:942-947.
14. Beckers M.M., Ruven H.J., Haas F.J., Doevendans P.A., ten Cate H., Prins M.H., et al. Single nucleotide polymorphisms in inflammation-related genes are associated with venous thromboembolism. Eur. J. Internal Med. 2010, 21:289-292.
15. Beemath A., Stein P.D., Skaf E., Al Sibae M.R., Alesh I. Risk of venous thromboembolism in patients hospitalized with heart failure. Am. J. Cardiol. 2006, 98:793-795.
16. Beijers H.J., Ferreira I., Spronk H.M., Bravenboer B., Dekker J.M., Nijpels G., et al. Body composition as determinant of thrombin generation in plasma: the Hoorn study. Arterioscler. Thrombo. Vasc. Biol. 2010, 30:2639-2647.
17. Bernstein C.N., Blanchard J.F., Houston D.S., Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb. Haemost. 2001, 85:430-434.
18. Bonderman D., Lang I.M. Risk factors for chronic thromboembolic pulmonary hypertension. Textbook of Pulmonary Vascular Disease 2011, 1253-1259. Springer.
19. Bonderman D., Jakowitsch J., Adlbrecht C., Schemper M., Kyrle P.A., Schonauer V., et al. Medical conditions increasing the risk of chronic thromboembolic pulmonary hypertension. Thromb. Haemost. 2005, 93:512-516.
20. Bouman A.C., Smits J.J., Cate Ten, Cate-Hoek Ten Markers of coagulation, fibrinolysis and inflammation in relation to post-thrombotic syndrome. J. Thromb. Haemost.: JTH 2012, 10:1532-1538.
21. Bouzeghrane F., Zhang X., Gevry G., Raymond J. Deep vein thrombosis resolution is impaired in diet-induced type 2 diabetic mice. J. Vasc. Surg. 2008, 48:1575-1584.
22. Brakenridge S.C., Henley S.S., Kashner T.M., Golden R.M., Paik D.H., Phelan H.A., et al. Comparing clinical predictors of deep venous thrombosis versus pulmonary embolus after severe injury: a new paradigm for posttraumatic venous thromboembolism. J. Trauma Acute Care Surg. 2013, 74:7-8.
23. Brotman D.J., Segal J.B., Jani J.T., Petty B.G., Kickler T.S. Limitations of -dimer testing in unselected inpatients with suspected venous thromboembolism. Am. J. Med. 2003, 114:276-282.
24. Brzezkova R., Fryba V., Chrz K., Krska Z., Kvasnicka J. Prolonged prophylaxis of thromboembolic disease in patients with colorectal surgical resections for malignancy. Rozhl. Chir. 2009, 88:642-648.
25. Carmeliet P., Stassen J.M., Van Vlaenderen I., Meidell R.S., Collen D., Gerard R.D. Adenovirus-mediated transfer of tissue-type plasminogen activator augments thrombolysis in tissue-type plasminogen activator-deficient and plasminogen activator inhibitor-1-overexpressing mice. Blood 1997, 90:1527-1534.
26. Chaari A., Ghadhoune H., Chakroune O., Abid H., Turki O., Bahloul M., et al. The use of a low dose hydrocortisone to prevent pulmonary embolism in patients with multiple trauma. Int. J. Clin. Pharm. 2013, 35:593-599.
27. Challis J.R., Lockwood C.J., Myatt L., Norman J.E., Strauss J.F., Petraglia F. Inflammation and pregnancy. Reprod. Sci. 2009, 16:206-215.
28. Chande N. Prevention of venous thromboembolism in hospitalized patients with inflammatory bowel disease. Inflamm. Bowel Dis. 2013, 19:669-671.
29. Chong A.Y., Lip G.Y. Viewpoint: the prothrombotic state in heart failure: a maladaptive inflammatory response?. Eur. J. Heart Fail. 2007, 9:124-128.
30. Cohen A.T., Gurwith M.M., Dobromirski M. Thromboprophylaxis in non-surgical cancer patients. Thromb. Res. 2012, 1:S137-45.
31. Cohen P.G. Estradiol induced inhibition of 11 beta-hydroxysteroid dehydrogenase 1: an explanation for the postmenopausal hormone replacement therapy effects. Med. Hypotheses 2005, 64:989-991.
32. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
33. Daly E., Vessey M.P., Hawkins M.M., Carson J.L., Gough P., Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996, 348:977-980.
34. Dammacco F., Vacca A., Procaccio P., Ria R., Marech I., Racanelli V. Cancer-related coagulopathy (Trousseau's syndrome): review of the literature and experience of a single center of internal medicine. Clin. Exp. Med. 2013, 13:85-97.
35. Danese S., Semeraro S., Papa A., Roberto I., Scaldaferri F., Fedeli G., et al. Extraintestinal manifestations in inflammatory bowel disease. World J. Gastroenterol. 2005, 11:7227.
36. Darvall K.A., Sam R.C., Silverman S.H., Bradbury A.W., Adam D.J. Obesity and thrombosis. Eur. J. Vasc. Endovasc. Surg. 2007, 33:223-233.
37. Davenport D.L., Vargas H.D., Kasten M.W., Xenos E.S. Timing and perioperative risk factors for in-hospital and post-discharge venous thromboembolism after colorectal cancer resection. Clinical and applied thrombosis/hemostasis: official. J. Int. Acad. Clin. Appl. Thromb./Hemost. 2012, 18:569-575.
38. Deatrick K.B., Obi A., Luke C.E., Elfline M.A., Sood V., Upchurch G.R., et al. Matrix metalloproteinase-9 deletion is associated with decreased mid-term vein wall fibrosis in experimental stasis DVT. Thromb. Res. 2013, 132:360-366.
39. Decousus H., Quéré I., Presles E., Becker F., Barrellier M.-T., Chanut M., et al. Superficial venous thrombosis and venous thromboembolism a large prospective epidemiologic study. Ann. Internal Med. 2010, 152:218-224.
40. Duzgun N., Ates A., Aydintug O.T., Demir O., Olmez U. Characteristics of vascular involvement in Behcet's disease. Scand. J. Rheumatol. 2006, 35:65-68.
41. de Wolf M.A., Wittens C.H., Kahn S.R. Incidence and risk factors of the post-thrombotic syndrome. Phlebology 2012, 27(Suppl. 1):85-94.
42. Eilertsen A.L., Hoibraaten E., Os I., Andersen T.O., Sandvik L., Sandset P.M. The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis. Maturitas 2005, 52:111-118.
43. Engbaek J., Bartholdy J., Hjortso N.C. Return hospital visits and morbidity within 60 days after day surgery: a retrospective study of 18,736 day surgical procedures. Acta Anaesthesiol. Scand. 2006, 50:911-919.
44. Eriksson B.I., Dahl O.E. Prevention of venous thromboembolism following orthopaedic surgery: clinical potential of direct thrombin inhibitors. Drugs 2004, 64:577-595.
45. Ferroni P., Riondino S., Portarena I., Formica V., La Farina F., Martini F., et al. Association between increased tumor necrosis factor alpha levels and acquired activated protein C resistance in patients with metastatic colorectal cancer. Int. J. Colorectal Dis. 2012, 27:1561-1567.
46. Folsom A.R., Boland L.L., Cushman M., Heckbert S.R., Rosamond W.D., Walston J.D. Frailty and risk of venous thromboembolism in older adults. J. Gerontol. A, Biol. Sci. Med. Sci. 2007, 62:79-82.
47. Geddings J.E., Mackman N. New players in haemostasis and thrombosis. Thromb. Haemost. 2014, 111:570-574.
48. Geerts W.H., Code K.I., Jay R.M., Chen E., Szalai J.P. A prospective study of venous thromboembolism after major trauma. N. Engl. J. Med. 1994, 331:1601-1606.
49. Gisondi P., Girolomoni G. Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors. Semin. Thromb. Hemost. 2009, 35:313-324.
50. Goldhaber S.Z., Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet 2012, 379:1835-1846.
51. Gonzalez-Ordonez A.J., Fernandez-Carreira J.M., Fernandez-Alvarez C.R., Venta Obaya R., Macias-Robles M.D., Gonzalez-Franco A., et al. The concentrations of soluble vascular cell adhesion molecule-1 and lipids are independently associated with venous thromboembolism. Haematologica 2003, 88:1035-1043.
52. Grainge M.J., West J., Card T.R. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 2010, 375:657-663.
53. Grossfeld A., Dekel S., Lerman Y., Sherman S., Atzmony L., Salai M., et al. Symptomatic venous thromboembolism in elderly patients following major orthopedic surgery of the lower limb is associated with elevated vitamin B12 serum levels. Clin. Biochem. 2013, 46:54-58.
54. Hanauer S.B. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm. Bowel Dis. 2006, 12:S3-S9.
55. Hancock H.S., Wang M., Gist K.M., Gibson E., Miyamoto S.D., Mourani P.M., et al. Cardiac findings and long-term thromboembolic outcomes following pulmonary embolism in children: a combined retrospective-prospective inception cohort study. Cardiol. Young 2013, 23:344-352.
56. Hayes K.C., Hull T.C.L., Delaney G.A., Potter P.J., Sequeira K.A.J., Campbell K., et al. Elevated serum titers of proinflammatory cytokines and CNS autoantibodies in patients with chronic spinal cord injury. J. Neurotrauma 2002, 19:753-761.
57. Heit J.A., Silverstein M.D., Mohr D.N., Petterson T.M., O'Fallon W.M., Melton L.J. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch. Intern. Med. 2000, 160:809-815.
58. Heit J.A., Kobbervig C.E., James A.H., Petterson T.M., Bailey K.R., Melton L.J. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann. Internal Med. 2005, 143:697-706.
59. Hollmann M.W., Strumper D., Durieux M.E. The poor man's epidural: systemic local anesthetics for improving postoperative outcomes. Med. Hypotheses 2004, 63:386-389.
60. Horlander K.T., Mannino D.M., Leeper K.V. Pulmonary embolism mortality in the United States, 1979-1998: an analysis using multiple-cause mortality data. Arch. Intern. Med. 2003, 163:1711-1717.
61. Huang V., Mishra R., Thanabalan R., Nguyen G.C. Patient awareness of extraintestinal manifestations of inflammatory bowel disease. J. Crohn's Colitis 2013, 7:e318-24.
62. Inanir A., Tural S., Yigit S., Kalkan G., Pancar G.S., Demir H.D., et al. Association of IL-4 gene VNTR variant with deep venous thrombosis in Behcet's disease and its effect on ocular involvement. Mol. Vision 2013, 19:675-683.
63. James A.H., Jamison M.G., Brancazio L.R., Myers E.R. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am. J. Obstet. Gynecol. 2006, 194:1311-1315.
64. Jezovnik M.K., Poredos P. Factors influencing the recanalisation rate of deep venous thrombosis. Int. Angiol. 2012, 31:169-175.
65. Jo J.Y., Lee M.Y., Lee J.W., Rho B.H., Choi W.I. Leukocytes and systemic inflammatory response syndrome as prognostic factors in pulmonary embolism patients. BMC Pulm. Med. 2013, 13:74.
66. Johannesdottir S.A., Schmidt M., Horvath-Puho E., Sorensen H.T. Autoimmune skin and connective tissue diseases and risk of venous thromboembolism: a population-based case-control study. J. Thromb. Haemost.: JTH 2012, 10:815-821.
67. Kabrhel C., Varraso R., Goldhaber S.Z., Rimm E.B., Camargo C.A. Prospective study of BMI and the risk of pulmonary embolism in women. Obesity (Silver Spring, Md). 2009, 17:2040-2046.
68. Kabrhel C., Varraso R., Goldhaber S.Z., Rimm E., Camargo C.A. Physical inactivity and idiopathic pulmonary embolism in women: prospective study. BMJ (Clin. Res. ed). 2011, 343:d3867.
69. Korswagen L.A., Bartelds G.M., Krieckaert C.L.M., Turkstra F., Nurmohamed M.T., van Schaardenburg D., et al. Venous and arterial thromboembolic events in adalimumabtreated patients with antiadalimumab antibodies: a case series and cohort study. Arthritis Rheum. 2011, 63:877-883.
70. Kostic A.D., Xavier R.J., Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology 2014, 146:1489-1499.
71. Larocca A., Cavallo F., Mina R., Boccadoro M., Palumbo A. Current treatment strategies with lenalidomide in multiple myeloma and future perspectives. Future Oncol. (London, England) 2012, 8:1223-1238.
72. Lee P.Y., Yun A.J., Bazar K.A. Acute coronary syndromes and heart failure may reflect maladaptations of trauma physiology that was shaped during pre-modern evolution. Med. Hypotheses 2004, 62:861-867.
73. Leon L., Giannoukas A.D., Dodd D., Chan P., Labropoulos N. Clinical significance of superficial vein thrombosis. Eur. J. Vasc. Endovasc. Surg. 2005, 29:10-17.
74. Leung G.G., Sivasankaran M.V., Choi J.J., Divino C.M. Risk factors of portal vein thrombosis in Crohn's disease patients. J. Gastrointest. Surg. 2012, 16:1199-1203.
75. Levi D., Goodman E.R., Patel M., Savransky Y. Critical care of the obese and bariatric surgical patient. Crit. Care Clin. 2003, 19:11-32.
76. Ludvigsson J.F., Welander A., Lassila R., Ekbom A., Montgomery S.M. Risk of thromboembolism in 14,000 individuals with coeliac disease. Br. J. Haematol. 2007, 139:121-127.
77. Maggi U., Rossi G., Avesani E.C., Artoni A., Caprioli F., Napolitano L., et al. Thrombotic storm in a teenager with previously undiagnosed ulcerative colitis. Pediatrics 2013, 131:e1288-91.
78. Mahemuti A., Abudureheman K., Aihemaiti X., Hu X.M., Xia Y.N., Tang B.P., et al. Association of interleukin-6 and C-reactive protein genetic polymorphisms levels with venous thromboembolism. Chin. Med. J. 2012, 125:3997-4002.
79. Makol A., Grover M., Guggenheim C., Hassouna H. Etanercept and venous thromboembolism: a case series. J. Med. Case Rep. 2010, 4:12.
80. Marcucci R., Abbate R., Fedi S., Gori A.M., Brunelli T., Bruni V., et al. Acquired activated protein C resistance in postmenopausal women is dependent on factor VIII: c levels. Am. J. Clin. Pathol. 1999, 111:769-772.
81. Martinod K., Demers M., Fuchs T.A., Wong S.L., Brill A., Gallant M., et al. Neutrophil histone modification by peptidylarginine deiminase 4 is critical for deep vein thrombosis in mice. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:8674-8679.
82. Matta F., Singala R., Yaekoub A.Y., Najjar R., Stein P.D. Risk of venous thromboembolism with rheumatoid arthritis. Thromb. Haemost. 2009, 101:134-138.
83. McLaughlin G.E. Sudden death in rheumatoid arthritis: pulmonary embolism-a fatal complication of iliopsoas bursitis. J. Clin. Rheumatol. 2002, 8:208-211.
84. Meesters E.W., Hansen H., Spronk H.M., Hamulyak K., Rosing J., Rowshani A.T., et al. The inflammation and coagulation cross-talk in patients with systemic lupus erythematosus. Blood Coagul. Fibrinolysis 2007, 18:21-28.
85. Miehsler W., Reinisch W., Valic E., Osterode W., Tillinger W., Feichtenschlager T., et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism?. Gut 2004, 53:542-548.
86. Minnema M.C., ten Cate H., van Beek E.J., van den Ende A., Hack C.E., Brandjes D.P. Effects of heparin therapy on fibrinolysis in patients with pulmonary embolism. Thromb. Haemost. 1997, 77:1164-1167.
87. Mitry E., Taleb-Fayad R., Deschamps A., Mansencal N., Lepere C., Declety G., et al. Risk of venous thrombosis in patients with pancreatic adenocarcinoma. Gastroenterol. Clin. Biol. 2007, 31:1139-1142.
88. Mustafa S., Weltermann A., Fritsche R., Marsik C., Wagner O., Kyrle P.A., et al. Genetic variation in heme oxygenase 1 (HMOX1) and the risk of recurrent venous thromboembolism. J. Vasc. Surg. 2008, 47:566-570.
89. Naeem M.A., Usman M., Latif M.K., Aamir M. The relationship of -dimer levels with risk for developing deep-vein thrombosis and/or pulmonary thromboembolism after orthopaedic trauma surgery. J. Ayub Med. Coll. Abbottabad: JAMC 2009, 21:113-116.
90. Navarro S., Ricart J.M., Medina P., Vaya A., Villa P., Todoli J., et al. Activated protein C levels in Behcet's disease and risk of venous thrombosis. Br. J. Haematol. 2004, 126:550-556.
91. Nguyen G.C., Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am. J. Gastroenterol. 2008, 103:2272-2280.
92. Nguyen G.C., Sharma S. Feasibility of venous thromboembolism prophylaxis during inflammatory bowel disease flares in the outpatient setting: a decision analysis. Inflamm. Bowel Dis. 2013, 19:2182-2189.
93. Nguyen G.C., Boudreau H., Harris M.L., Maxwell C.V. Outcomes of obstetric hospitalizations among women with inflammatory bowel disease in the United States. Clinical gastroenterology and hepatology: the official clinical practice. J. Am. Gastroenterol. Assoc. 2009, 7:329-334.
94. Papay P., Miehsler W., Tilg H., Petritsch W., Reinisch W., Mayer A., et al. Clinical presentation of venous thromboembolism in inflammatory bowel disease. J. Crohn's Colitis 2013, 7:723-729.
95. Parambil J.G., Savci C.D., Tazelaar H.D., Ryu J.H. Causes and presenting features of pulmonary infarctions in 43 cases identified by surgical lung biopsy. Chest 2005, 127:1178-1183.
96. Peeters P.J., Bazelier M.T., Uitdehaag B.M., Leufkens H.G., De Bruin M.L., de Vries F. The risk of venous thromboembolism in patients with multiple sclerosis: the clinical practice research datalink. J. Thromb. Haemost.: JTH 2016, 2014.
97. Pengo V., Lensing A.W.A., Prins M.H., Marchiori A., Davidson B.L., Tiozzo F., et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N. Engl. J. Med. 2004, 350:2257-2264.
98. Petrauskiene V., Falk M., Waernbaum I., Norberg M., Eriksson J.W. The risk of venous thromboembolism is markedly elevated in patients with diabetes. Diabetologia 2005, 48:1017-1021.
99. Pleet J.L., Vaughn B.P., Morris J.A., Moss A.C., Cheifetz A.S. The use of pharmacological prophylaxis against venous thromboembolism in hospitalised patients with severe active ulcerative colitis. Aliment. Pharmacol. Ther. 2016, 2014.
100. Polosa R., Cacciola R.R., Prosperini G., Spicuzza L., Morjaria J.B., Di Maria G.U. Endothelial-coagulative activation during chronic obstructive pulmonary disease exacerbations. Haematologica 2008, 93:1275-1276.
101. Ramagopalan S.V., Wotton C.J., Handel A.E., Yeates D., Goldacre M.J. Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study. BMC Med. 2011, 9:1.
102. Rizkallah J., Man S.F., Sin D.D. Prevalence of pulmonary embolism in acute exacerbations of COPD: a systematic review and metaanalysis. Chest 2009, 135:786-793.
103. Robson S.C., White N.W., Aronson I., Woollgar R., Goodman H., Jacobs P. Acute-phase response and the hypercoagulable state in pulmonary tuberculosis. Br J. Haematol. 1996, 93:943-949.
104. Rothberg M.B., Lindenauer P.K., Lahti M., Pekow P.S., Selker H.P. Risk factor model to predict venous thromboembolism in hospitalized medical patients. J. Hosp. Med. 2011, 6:202-209.
105. Rumley A., Emberson J.R., Wannamethee S.G., Lennon L., Whincup P.H., Lowe G.D. Effects of older age on fibrin -dimer, C-reactive protein, and other hemostatic and inflammatory variables in men aged 60-79 years. J. Thromb. Haemost.: JTH. 2006, 4:982-987.
106. Sabit R., Thomas P., Shale D.J., Collins P., Linnane S.J. The effects of hypoxia on markers of coagulation and systemic inflammation in patients with COPD. Chest 2010, 138:47-51.
107. Saghazadeh A., Hafizi S., Rezaei N. Inflammation in venous thromboembolism: cause or consequence?. Int. Immunopharmacol. 2015, 28:655-665.
108. Salobir B., Sabovic M. A metabolic syndrome independent association between overweight, fibrinolysis impairment and low-grade inflammation in young women with venous thromboembolism. Blood Coagul. Fibrinolysis 2006, 17:551-556.
109. Savchenko A.S., Martinod K., Seidman M.A., Wong S.L., Borissoff J.I., Piazza G., et al. Neutrophil extracellular traps form predominantly during the organizing stage of human venous thromboembolism development. J. Thromb. Haemost.: JTH 2014.
110. Shbaklo H., Holcroft C.A., Kahn S.R. Levels of inflammatory markers and the development of the post-thrombotic syndrome. Thromb. Haemost. 2009, 101:505-512.
111. Smeeth L., Cook C., Thomas S., Hall A.J., Hubbard R., Vallance P. Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet 2006, 367:1075-1079.
112. Solem C.A., Loftus E.V., Tremaine W.J., Sandborn W.J. Venous thromboembolism in inflammatory bowel disease. Am. J. Gastroenterol. 2004, 99:97-101.
113. Sollid L.M. Coeliac disease: dissecting a complex inflammatory disorder. Nat. Rev. Immunol. 2002, 2:647-655.
114. Sonnevi K., Tchaikovski S.N., Holmstrom M., Antovic J.P., Bremme K., Rosing J., et al. Obesity and thrombin-generation profiles in women with venous thromboembolism. Blood Coagul. Fibrinolysis 2013, 24:547-553.
115. Sonoda K., Ikeda S., Mizuta Y., Miyahara Y., Kohno S. Evaluation of venous thromboembolism and coagulation-fibrinolysis markers in Japanese patients with inflammatory bowel disease. J. Gastroenterol. 2004, 39:948-954.
116. Stein A., Panjwani A., Sison C., Rosen L., Chugh R., Metz C., et al. Pilot study: elevated circulating levels of the proinflammatory cytokine macrophage migration inhibitory factor in patients with chronic spinal cord injury. Arch. Phys. Med. Rehabil. 2013, 94:1498-1507.
117. Stinnett J.M., Pendleton R., Skordos L., Wheeler M., Rodgers G.M. Venous thromboembolism prophylaxis in medically ill patients and the development of strategies to improve prophylaxis rates. Am. J. Hematol. 2005, 78:167-172.
118. Sultan A.A., Tata L.J., West J., Fiaschi L., Fleming K.M., Nelson-Piercy C., et al. Risk factors for first venous thromboembolism around pregnancy: a population-based cohort study from the United Kingdom. Blood 2013, 121:3953-3961.
119. Tang B., Chen Y.K., Luo W.J., Fu J., Sun J.M. Association between interleukin-10-1082A/G-819C/T and -592C/A polymorphisms with deep venous thrombosis. Hum. Immunol. 2014, 75:203-207.
120. Tinsley A., Naymagon S., Trindade A.J., Sachar D.B., Sands B.E., Ullman T.A. A survey of current practice of venous thromboembolism prophylaxis in hospitalized inflammatory bowel disease patients in the United States. J. Clin. Gastroenterol. 2013, 47:e1-e6.
121. Tshifularo N., Arnold M., Moore S.W. Thromboembolism and venous thrombosis of the deep veins in surgical children-an increasing challenge?. J. Pediatr. Surg. 2011, 46:433-436.
122. Tuttolomondo A., Di Raimondo D., Pecoraro R., Arnao V., Pinto A., Licata G. Inflammation in ischemic stroke subtypes. Curr. Pharm. Des. 2012, 18:4289-4310.
123. Vaidyula V.R., Criner G.J., Grabianowski C., Rao A.K. Circulating tissue factor procoagulant activity is elevated in stable moderate to severe chronic obstructive pulmonary disease. Thromb. Res. 2009, 124:259-261.
124. van Minkelen R., de Visser M.C., Houwing-Duistermaat J.J., Vos H.L., Bertina R.M., Rosendaal F.R. Haplotypes of IL1B, IL1RN IL1R1, and IL1R2 and the risk of venous thrombosis. Arterioscler. Thromb. Vasc. Biol. 2007, 27:1486-1491.
125. von Haehling S., von Bardeleben R.S., Kramm T., Thiermann Y., Niethammer M., Doehner W., et al. Inflammation in right ventricular dysfunction due to thromboembolic pulmonary hypertension. Int. J. Cardiol. 2010, 144:206-211.
126. Wallaert J.B., De Martino R.R., Marsicovetere P.S., Goodney P.P., Finlayson S.R., Murray J.J., et al. Venous thromboembolism after surgery for inflammatory bowel disease: are there modifiable risk factors? Data from ACS NSQIP. Dis. Colon Rectum 2012, 55:1138-1144.
127. Walley K.R., Russell J.A. Protein C-1641 AA is associated with decreased survival and more organ dysfunction in severe sepsis. Crit. Care Med. 2007, 35:12-17.
128. Wang Z., Klipfell E., Bennett B.J., Koeth R., Levison B.S., DuGar B., et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011, 472:57-63.
129. Wellen K.E., Hotamisligil G.S. Inflammation, stress, and diabetes. J. Clin. Invest. 2005, 115:1111-1119.
130. White R.H. The epidemiology of venous thromboembolism. Circulation 2003, 107:I-4.
131. Xenos E.S., Vargas H.D., Davenport D.L. Association of blood transfusion and venous thromboembolism after colorectal cancer resection. Thromb. Res. 2012, 129:568-572.
132. Yuhara H., Steinmaus C., Corley D., Koike J., Igarashi M., Suzuki T., et al. Meta-analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 2013, 37:953-962.
133. Zee R.Y., Glynn R.J., Cheng S., Steiner L., Rose L., Ridker P.M. An evaluation of candidate genes of inflammation and thrombosis in relation to the risk of venous thromboembolism: the women's genome health study. Circ. Cardiovasc. Genet. 2009, 2:57-62.
134. Zee R.Y., Bubes V., Shrivastava S., Ridker P.M., Glynn R.J. Genetic risk factors in recurrent venous thromboembolism: a multilocus, population-based, prospective approach. Clin. Chim. Acta; Int. J. Clin. Chem. 2009, 402:189-192.
135. Zhang C.Q., Huang H., Zhao Z., Tang X.Z., Wang B., He F., et al. Gene expression profile related to inflammation in rat model of traumatic deep vein thrombosis. Chin. J. Traumatol. 2007, 10:206-212.
136. Zoller B., Li X., Sundquist J., Sundquist K. Autoimmune diseases and venous thromboembolism: a review of the literature. Am. J. Cardiovasc. Dis. 2012, 2:171-183.